A budget impact analysis considering a public health institution perspective was performed. The expenses of the Mexican Health Care System due to a vaccination program (vaccines, vaccination program, medical visits, treatment of influenza and influenza related complications, hospitalization and intensive care unit cost) were simulated with MF59 or SPL versus NOVA in elderly population affected by an influenza pandemic. A case scenario of high incidence influenza (5% of population) with three sub-scenarios was designed: a) 20%, b) 30%, and c) 50% of patients developing complications related to influenza. A systematic literature review was designed in order to include the most recent information about vaccines effectiveness measured as the ability of provide seroprotection against Influenza A/H1N1 strain and pandemic historical influenza incidences recommended by World Health Organization. Use of resources and cost matrixes were designed with the most recent data of main Public Health Institution in Mexico, which attends about fifty percent of the total population in Mexico. RESULTS: The cost of treatment of influenza and complications related to influenza were estimated in US$38.84 and US$5,052.06, respectively. A budget impact model (BIM) was developed to estimate the economic impact of intraconazole in prophylaxis of invasive fungal infections (IFI) in patients with neutropenia in Spain. METHODS: A BIM was developed using published data for disease prevalence, population growth, pharmaceutical ex-factory prices, health care resource consumption and market shares forecasting for Spain. This study was developed under the perspective of the health care system and time horizon considered was 5 years with an annual discount rate of 3%. According to a panel of clinical experts, drugs considered in this study were all different "azoles" currently used in prophylaxis in Spain regardless whether they have been authorized for this purpose or not. These are the following ones: itraconazole, posaconazole, fluconazole and voriconazole. This model estimated the cost of this disease for the Spanish health care system with and without the partial replacement (from 5% to 15%) of posaconazale by itraconazole. All costs were referred to year 2009. RESULTS: According to official statistic, target population with hematologic cancers in prophylaxis of IFI in Spain would be around 70,000 patients in the first year, arriving at 75,000 in the 5 th year. Direct medical costs for the next 5 years were estimated at a1424 million before the replacement of posaconazole by itraconazole. Costs were estimated at a1423 million whether this replacement would take place. CONCLUSIONS: The replacement of posaconazale by itraconazole in a very low percentage (from 5% to 15%) would represent a savings of a830,000 for the Spanish health care system in the next 5 years. results from the budget impact model show that in the first scenario (first line therapy) the combination tenofovir-emtricitabine-efavirenz is cost saving to the health care system compared to three of the most effective HAART regimens: AZT/3TC-LPV/r, 3TC/ABC-SQV and TDF-3TC-EFV and saves 141 981,46 Euro, 83461,53 Euro and a2445.99, respectively for one year. The second scenario (second line therapy) is indicated only for certain patients according to their virology status. In this scenario the regimen TDF-FTC-EFV is cost saving to the health care system in comparison with TDF-3TC-EFV and saves a2445.99. CONCLUSIONS: TDF-FTC-EFV is cost saving for the health care system compared to three of the most effective regimens in Bulgaria. The combination is much appropriate as first line HAART.
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PIN11 BUDGET IMPACT ANALYSIS OF NEW ANTRIRETROVIRAL MEDICINES FOR TREATMENT OF HIV PATIENTS IN BULGARIA
Dimitrova MJ, Stefanova MT, Petrova GI Medical University Sofia, Faculty of Pharmacy, Sofia, Bulgaria OBJECTIVES: To analyze the budget impact of two newly registered for Bulgaria antiretroviral medicines tenofovir and emtricitabine for treatment of HIV infection. The point of view is that of health care system and time horizon is one year. METHODS: Budget impact model was created for antiretroviral medicinal therapies for first and second line treatment. Two scenarios were analyzed for highly active antiretroviral therapy (HAART) including 12 medicines combinations for first line and 7 combinations for second line therapy. Health care resources included in the model are medicines, physician consultation first and 11 follow up attendances, 12 clinical, 3 virology and 6 immunology tests. In the model was varied the cost of the medicines therapy and number of patients. RESULTS: Untill June 2009 in Bulgaria are registered 991 HIV positive patients and near 230 of them are on highly active antiretroviral therapy (HAART)-first or second line depending on their virology status. Preliminary results from the budget impact model show that in the first scenario (first line therapy) the combination tenofovir-emtricitabine-efavirenz is cost saving to the health care system compared to three of the most effective HAART regimens: AZT/3TC-LPV/r, 3TC/ABC-SQV and TDF-3TC-EFV and saves 141 981,46 Euro, 83461,53 Euro and a2445.99, respectively for one year. The second scenario (second line therapy) is indicated only for certain patients according to their virology status. In this scenario the regimen TDF-FTC-EFV is cost saving to the health care system in comparison with TDF-3TC-EFV and saves a2445.99. CONCLUSIONS: TDF-FTC-EFV is cost saving for the health care system compared to three of the most effective regimens in Bulgaria. The combination is much appropriate as first line HAART.
PIN12 BUDGET IMPACT ANALYSIS OF THREE CANDINS IN THE TREATMENT OF INVASIVE CANDIDIASIS IN ADULT NON-NEUTROPENIC PATIENTS IN SPAIN
García M, Martí B, Ferro B Health Outcomes Research, Pfizer, Spain OBJECTIVES: Three candins had been approved for the treatment of invasive candidiasis (IC). Different drugs are associated with different needs for dose adjustment which might affect the total cost. The aim of this study was to estimate the budget impact of caspofungin, micafungin and anidulafungin in the treatment of 100 patients with invasive candidiasis from the perspective of the Spanish hospital pharmacy setting. METHODS: Possible scenarios varying percentage of doses adjustment required were also considered to assess the global impact on costs. Prices for each presentation were obtained from the Spanish database "portalfarma", expressed in a2008. Only drug acquisition costs were considered into the analysis. Total cost for the three candins was finally displayed. RESULTS: Cost per episode associated with the use of anidulafungin remained constant at a6000. When considering caspofungin, cost-per-episode varies from a4665 to a7991 depending on the patient's weight and hepatic dysfunction. Finally micafungin total cost-per-episode was estimated at a6,000 when low doses where required while higher doses based on inadequate respond had a cost of a10,714 per IC episode. Total cost based on a hypothetic cohort of 100 patients with IC treated with anidulafungin would be of a600,000, while the cost of caspofungin and micafungin on the base case will be a637,084 and a632,998, respectively, depending on dose adjustment required. CONCLUSIONS: Patients treated with Anidulafungin did not required dose adjustment unlike caspofungin and micafungin. The use of anidulafungin in the treatment of adult non-neutropenic patients with invasive candidiasis is a cost saving treatment option that allows a better control of antifungal budget based on a lower total cost per episode, from the pharmacy department perspective in Spain.
PIN13 BUDGET IMPACT MODEL: LEVOFLOXACIN VS STANDARD THERAPIES IN THE TREATMENT OF INPATIENT CAP
GlaxoSmithKline Spa, Verona, Italy, 2 GlaxoSmithKline Verona -Italy, Verona, Italy OBJECTIVES: To develop a Budget Impact Model (BIM) to estimate the financial consequences of the use of levofloxacin for the treatment of community-acquired pneumonia (CAP) in Italian Hospitals to support health decision makers. METHODS: We developed a BIM for levofloxacin that compares current treatments for CAP, their efficacy and safety and the resource use and costs as apply to the population of interest. Several dimensions were considered: drug consumption, frequency and days of treatment, health care professional costs, disposable (material), hospitalization costs and need of a second line treatment. Different scenarios in antibiotic treatment of CAP were included for comparison, such as i.v. therapy or switch therapy and levoxacin is compared to current alternative in monotherapy and in combination therapy. RESULTS: CAP is an infection still associated to considerable rates of morbidity and mortality and with important consequences from the social and economic perpspective. In Italy the annual incidence of hospitalization due to CAP is about 3 cases every 1000 habitants, with rather high mortality rates: from 15/100.000 cases of the national mean to 70/100.000 cases for subjects older than 65 years. More than 90% of CAP costs are associated to hospitalizations (500 million euro. The model we developed results in an interactive tool that allows users (payers) to understand the relation between the characteristics of their scenario and the possible budget consequences of the different treatment choices and informs them about the most affordable option among current treatments for CAP (including levofloxacin) according to the features of their own scenario CONCLUSIONS: BIMs are primarily intended to IMs are primarily intended to inform health care decision makers, especially those who are responsible for national, regional, or local health care budgets. For this reason methodology and results were reviewed in an external engagement with payers to validate the model in a real scenario. (Combivir®), associated with lopinavir/r, we observed a change in PEP prescription compared to 2007, which explained at 72.5% the cost's increase observed. CONCLUSIONS: The review of cost-effectiveness suggests that PEP may be cost-effective only in certain population subgroups. In our hospital only targeted patients at high-risk received PEP according to guidelines. The cost difference between TDF FTC and AZT 3TC highlighted here will enable us to begin a revision of local recommendations. To analyze the economic consequences for the Intensive Care Units (ICU) of a faster diagnose and when indicated earlier shift in therapy using PCR compared with a traditional blood culture. METHODS: A decision-tree based costing model was designed to compare the two approaches to diagnosing (blood culture alone versus PCR plus blood culture). The model compares the costs of the diagnostic methods, costs of medicines as well as costs of LOS at the ICU for the two alternatives. The data for the costing model was based on data for a half year of patients at Copenhagen University Hospital in 2008 having an invasive candida infection (n 10), and all costs were from a Danish perspective. RESULTS: All patients in risk of developing invasive candida infection are treated with fluconazol until diagnosed positive. Based on a national surveillance of patterns of resistance up to 35% of the patients will be shifted to an echinocandin after diagnose. A faster diagnose and early shift in therapy with echinocandin will imply in average an extra medicine costs between a 254-267. However, at the same time LOS at ICU will in average be reduced by 1.4 days, which will result in savings as high as a4859. Diagnose with PCR and use of echinocandin for the 35% of the relevant patients could therefore result in savings up to a4605 per patient. CONCLUSIONS: Rapid diagnose with PCR and early shift in therapy to echinocandin is cost-effective. However, different budgets (including the DRG payment) at the hospital are affected, why silo thinking might be a barrier, when deciding upon the cost-effective strategy.
PIN14 BUDGET IMPACT OF HIV POST-EXPOSURE PROPHYLAXIS: AN EXAMPLE OF HOSPITAL POINT OF VIEW AFTER NEW RECOMMENDATIONS IN FRANCE

PIN15 THE ECONOMIC IMPLICATION OF A RAPID DIAGNOSE AND EARLY SHIFT IN THERAPY IN PATIENTS WITH INVASIVE CANDIDA INFECTION
PIN16 COST-EFFECTIVENESS OF HEPTAVALENT PNEUMOCOCCAL CONJUGATE VACCINE (PCV-7) IN MEXICO
Carlos F 1 , Mercado G 2 , Aguirre A 2 , Vargas A 1 , Bierschwale H 2 1 R A C Salud Consultores, SA de CV, Ciudad de Mexico, Distrito Federal, Mexico, 2 Wyeth México, Naucalpan, Mexico OBJECTIVES: Streptococcus pneumoniae is one of the most frequent causes of invasive(IPD) and non-invasive infections(Non-IPD), causing 1.6 million deaths worldwide in 2002. PCV-7 provides a reliable protection for children 2 years old. We aimed to perform an economic evaluation of three doses plus a booster (3 1) compared to an abbreviated scheme (2 1) and with non-vaccination. METHODS: We developed a Markov model of ten annual cycles to estimate the costs and outcomes for a birth cohort of 1,955,284. Another model was designed to estimate the herd immunity effects during a year in the non-vaccinated population,98% coverage rate was assumed.Efficacy data from published sources was adjusted by serotype coverage and all costs reflect local practice.Direct medical costs included the immunization program, medical attention of IPD/Non-IPD and sequels of meningitis.All costs (discounted with an annual rate of 5%) were calculated in 2008 Mexican Pesos (MXP) and then expressed in US dollars (USD) using an exchange rate of 1 USD to 11.14 MXP (exchange rate by the time the study was performed). Disability-adjusted life years (DALY) were estimated following standard methods and assumptions. RESULTS: For the vaccinated cohort, the full scheme is a cost-saving intervention, costing US$10 million less than the abbreviate scheme and US$51 million less than non-vaccination. Adding the herd immunity benefits, overall savings increases to US$17.40 million (benefit : cost ratio 1.08) compared to (2 1) scheme and reaches US$121.19 million (benefit : cost ratio 1.54) compared with non-vaccination.The DALY averted with the full scheme are 35,988 and 172,813 compared to (2 1) scheme and non-vaccination, respectively. CONCLUSIONS: The full scheme (3 1) of PCV-7 had lower costs and better health outcomes when compared to both an abbreviated scheme (2 1) and non-vaccination, even if herd immunity is not taken into account.Although the 3 1 schedule is dominant the 2 1 schedule remains highly cost effective vs. no vaccination at all.
PIN17 THE COST OF ROTAVIRUS GASTROENTERITIS IN YOUNG CHILDREN IN FOUR EUROPEAN COUNTRIES: A STUDY IN PRIMARY CARE
Curran D 1 , Giaquinto C 2 , Diez-Domingo J 3 , Patrzalek M 4 , Pazdiora P 5 , Rosillon D 6 1 Omega Research, Dublin 9, Ireland, 2 University of Padova, Padova, Veneto, Italy, 3 C.S.I.S.P. (Center for Public Health Research)., Valencia, Spain, 4 25-339 Kielce ul.Zagórska, Kielce, Poland, 5 Charles University Pilsen, Pilsen, Czech Republic, 6 GSK, Rixensart, Belgium OBJECTIVES: To investigate the resource use and cost of rotavirus gastroenteritis (RVGE) in children aged 5 years presenting to primary care in four European countries, Italy, Spain, the Czech Republic and Poland. METHODS: This observational, prospective study collected data from children aged 5 years presenting to primary care (general practitioners and paediatricians) with acute gastroenteritis (defined as diarrhoea for 14 days) and a positive test for rotavirus. Severity of RVGE was assessed using the Vesikari score. Parents completed a cost questionnaire at a followup visit or phone call 14 days after the episode, recording information on: direct medical costs (physician visits and contacts including the initial visit, use of medication, rehydration solutions and nutritional products); direct non-medical costs (transport, supervision/carer costs, other costs); and indirect costs (days lost at work or school/daycare). All costs were recorded in 2006 Euros. RESULTS: Cost data were available for 502 children, of whom 126 were in Italy, 217 in Spain, 87 in Poland and 72 in the Czech Republic. A total of 65% of the children (n 326) were aged 0-24 months, 52% (n 263) were male, and 82% (n 410) were rated as moderate/severe using the Vesikari score. The mean total societal cost per child was a170.6 in Italy, a169.7 in Spain, a44.0 in Poland and a37.6 in the Czech Republic. The share of the total societal cost borne by the family was highest in Italy (57.5%), compared with 55.0% in Poland, 48.3% in Spain and 35.9% in the Czech Republic. CONCLU-SIONS: Paediatric RVGE presenting to primary care is associated with substantial direct and indirect costs, a high proportion of which are borne by families. These data will be valuable in economic evaluations of paediatric rotavirus vaccination. Acknowledgements to the SPRIK investigators, VIVA Spanish investigators, José Baldó, Nadia Meyer and Montse Soriano-Gabarró
PIN18 THE COST BURDEN OF ACUTE GASTROENTERITIS IN INFANTS AND YOUNG CHILDREN ATTENDING DAYCARE CENTRES IN FRANCE
Curran D 1 , Grimpel E 2 , Meyer N 3 , Pircon JY 3 1 Omega Research, Dublin 9, Ireland, 2 Hopital Trousseau, Paris, France, 3 GSK, Rixensart, Belgium OBJECTIVES: To investigate the cost of acute gastroenteritis (AGE) in children aged 3 years attending daycare centres in France. METHODS: This observational, prospective study was conducted at 15 daycare centres in Paris, France. Children were eligible for the study if they had an episode of AGE (defined as 3 loose stools within 24 hours, lasting for 14 days) before their third birthday. Parents completed a cost questionnaire for the affected child and household contacts (a person spending at least 50% of nights in the same home) who also experienced AGE in the 14 days before or after onset of gastroenteritis in the affected child. Information on direct medical costs (general practitioner or paediatrician visits and phone consultations, hospitalisations, emergency room visits, and use of medication, rehydration solutions and nutritional products); direct non-medical costs (transport, supervision/carer costs, other costs); and indirect costs (lost workdays) was recorded in 2006 Euros. RESULTS: Cost data were available for 71 episodes in 62 subjects (57 children attending daycare and 5 household contacts) of the 113 subjects in the study. Of the children attending daycare, 47% were male and 86% were aged 24 months. Most episodes (67%) were scored as mild/moderate using the Vesikari scale and 21% tested positive for rotavirus. The mean societal cost was a253.6 (SD 409.3) per episode, of which direct medical costs accounted for a93.2 (37%), non-medical direct costs a16.0 (6%) and indirect costs a144.4 (57%). Most of the total cost (63%) was borne by families, reflecting the importance of indirect costs. Rotavirus-positive episodes (n 15) had higher mean total costs than rotavirus-negative episodes (n 51), at a437.7 (SD a527.1) and a172.0 (SD a304.0) per episode, respectively. CONCLUSIONS: These data show the importance of indirect costs borne by families, and provide useful information for economic evaluations of paediatric rotavirus vaccination. 
PIN19 TREATMENT COSTS FOR CHRONIC HEPATITIS B (CHB) IN
